Shattuck Labs
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
500 W 5th St Ste 1200, Austin, Texas, 78...Phone Number
(512) 900-4690Website
www.shattucklabs.comRevenue
<$5 MillionStock Symbol
STTKIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
3
1
1
1
About Shattuck Labs
Shattuck Labs is a clinical-stage biotechnology company focused on research and development of innovative biologic medicines. Founded in 2016 and publicly traded on NASDAQ, the company specializes in developing bi-functional fusion proteins for treating cancer and autoimmune diseases. Shattuck's proprietary technology platforms include the Agonist Redirected Checkpoint (ARC) platform and the Gamma Delta T Cell Engager (GADLEN) platform, both designed to create novel therapeutic approaches. The company currently has multiple Phase 1 clinical trials underway for its product candidates. Headquartered in the United States, Shattuck maintains offices in both Austin, Texas and Durham, North Carolina, supporting its ongoing research and clinical development programs.Explore more
Shattuck Labs Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Shattuck Labs your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Shattuck Labs launches new products
Congratulate Masked Content for being promoted to Masked Content at Shattuck Labs
Check out if Shattuck Labs is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Shattuck Labs has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Shattuck Labs recently announced quarterly report
Check if Shattuck Labs has recently received funding, and reach out quickly before it becomes old news!
Click to see if Shattuck Labs had a recent Job posting/layoffs
Shattuck Labs, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Shattuck Labs
Find 3 more new buyers
Compare Similar Companies to Shattuck Labs
Compare insights from companies similar to Shattuck Labs, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$462.1M
1994
TC
Tracy ClementeChief People Officer & Chief Human Resources Officer
Company Profile Activity
Activity Insights
Shattuck Labs is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Shattuck Labs is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Shattuck Labs.
Shattuck Labs financials insights
Gather financial insights about Shattuck Labs, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$7M
2020
Multiple Rounds
$345.4M
Shattuck Labs Tech Stack
A closer look at the technologies used by Shattuck Labs
Most Recent Scoops
Project
Shattuck Labs has announced that SL-325 has become the first antibody to generate clinical data for blockade of the DR3 receptor (TL1A receptor), targeting inflammatory bowel diseases including ulcerative colitis and Crohn's disease in a market predicted to exceed $40 billion in global revenue.
Medical Research, Clinical Operations
Project
Shattuck Labs has completed its Phase I clinical trial of SL-325 in healthy volunteers, reporting that SL-325 was well-tolerated across all doses, achieved complete DR3 receptor occupancy at the lowest dose tested, demonstrated no evidence of DR3 agonism, and produced a low anti-drug antibody rate of 3.7%, supporting the potential for extended subcutaneous dosing intervals via an auto-injector pen.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Shattuck Labs has confirmed through Phase I human data that SL-325 is a pure DR3 blocking antibody, with no evidence of lymphocyte proliferation, serum cytokine changes, or cell activation markers observed in any participant, and no increase in serum TL1A levels detected.
Medical Research, Pharmaceuticals
Project
Shattuck Labs has developed a subcutaneous formulation of SL-325 at 150 mg/mL in a 2 mL auto-injector volume, with accelerated stability data predicting a 2-year shelf life at 4°C, and plans to conduct a Phase I intravenous-versus-subcutaneous bioavailability study concurrently with the Phase II Crohn's disease study to support conversion to subcutaneous administration in Phase III.
Product Development, Medical Research, Pharmaceuticals
Project
Pharmaceuticals, Clinical Operations
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Shattuck Labs
Sign Up For FreeTo access detailed company insights
Shattuck Labs is a clinical-stage biotechnology company focused on research and development of innovative biologic medicines. Founded in 2016 and publicly traded on NASDAQ, the company specializes in developing bi-functional fusion proteins for treating cancer and autoimmune diseases. Shattuck's proprietary technology platforms include the Agonist... Read More
